New Independent Study Establishes the Octave MSDA Test as an Objective Measure to Distinguish True MS Relapse from Pseudoexacerbation
The study shows the MSDA Test delivers an objective, quantifiable measure of inflammatory disease activity to distinguish true relapse from pseudoexacerbation, a common challenge in today’s standard of care, and outperforms neurofilament light (NfL) alone.
Octave Bioscience, Inc., a commercial-stage precision neurology company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced publication of an independent, investigator-initiated study in the journal Neurology and Therapy evaluating the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in one of the most consequential judgment calls in MS care, whether a patient’s new or worsening symptoms reflect a true inflammatory relapse or a pseudoexacerbation.
Entitled Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation, the retrospective observational study enrolled 66 people with relapsing multiple sclerosis at a single academic medical center. Researchers compared blood-based MSDA Test Disease Activity Scores with MRI findings to evaluate the test’s ability to distinguish true inflammatory relapse from pseudoexacerbation. MRI evidence of gadolinium-enhancing lesions served as the reference standard for active inflammatory disease, and investigators also compared the performance of the multi-protein MSDA Test with neurofilament light chain (NfL), a commonly studied biomarker of neuronal injury.
